Replimune Group Inc. received FDA approval for Tudriqev, its first drug targeting a difficult form of skin cancer, marking a major milestone for the biotech company. Despite earlier rejections and concerns over clinical data quality, the FDA granted accelerated approval, boosting investor confidence. Following the news, Replimune's stock rose by 8.71%, and BMO Capital maintained an "Outperform" rating, signaling expectations of strong future performance. This approval positions Replimune as a notable player in innovative cancer treatments with a market cap of about $1.08 billion.
Berkshire Hathaway will release its Q2 2026 earnings on August 8, with analysts expecting earnings of $5.04 per share and revenue of $96.52 billion. The company has been actively buying back up to $11 billion of its own shares, signaling management's...
Klépierre, a leading European shopping mall operator, announced it has 286,861,172 shares and nearly the same number of exercisable voting rights as of July 31, 2026. The company's portfolio is valued at €21.8 billion, comprising large shopping cente...
Klépierre, a leading European shopping center operator, disclosed its total number of shares and voting rights as of July 31, 2026. The company has 286,861,172 shares and 286,793,348 exercisable voting rights. Klépierre's portfolio is valued at €21.8...
Credit Agricole S.A. announced the publication of its 2026 half-year financial report via an amendment to its 2025 Universal Registration Document, filed with the French financial regulator AMF on August 7, 2026. The report is publicly accessible on ...
Scotiabank increased its price target for BCE Inc. to C$40 and maintained an "Outperform" rating following BCE's strong Q2 2026 results. The company reported adjusted earnings of C$0.65 per share, a 3.2% year-over-year increase, and total revenues ro...
